PHS
MLYS icon

PFM Health Sciences’s Mineralys Therapeutics MLYS Stock Holding History

PFM Health Sciences’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68M Sell
62,418
-80,259
-56% -$2.2M 0.14% 94
2026
Q1 		$3.87M Buy
142,677
+95,040
+200% +$2.79M 0.35% 68
2025
Q4 		$1.73M Buy
+47,637
New +$1.91M 0.17% 70

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PFM Health Sciences's MLYS Position: Q2 2026 in Review

PFM Health Sciences reduced its Mineralys Therapeutics (MLYS) stake by 56% in Q2 2026, selling an estimated $2.2M and leaving 62,418 shares worth $1.68M. The position accounts for 0.14% of the portfolio, ranked #94.

PFM Health Sciences first reported a position in MLYS in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.87M in Q1 2026. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • PFM Health Sciences held 62,418 shares of Mineralys Therapeutics worth $1.68M as of Q2 2026.
  • PFM Health Sciences sold 80,259 Mineralys Therapeutics shares in Q2 2026, an estimated $2.2M.
  • Mineralys Therapeutics made up 0.14% of PFM Health Sciences's portfolio in Q2 2026, its #94 holding.
  • PFM Health Sciences first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • PFM Health Sciences's Mineralys Therapeutics position peaked at $3.87M in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.